DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES

摘要

Formula (I) Compounds of formula (I), and stereoisomers, solvates, tautomers and pharmaceutically acceptable salts of formula (I), wherein W1, W2, X, Y, Z are as defined herein, for use in therapy. Also claimed is the use of compounds of formula (I) for use in the treatment of cancer, e.g. brain cancer, preferably glioma. Most preferably, R1 is a hydroxy group or a triphosphate. Most preferably, R2 is hydroxyl. Most preferably, R3 is H. Most preferably, X is either an aldehyde or CH2OH. Preferably, the compound of formula (I) is 5-hydroxymethyl-2’deoxycytidine or 5-formyl-2’deoxycytidine. The tumour to be treated may overexpress CDA, or may express CDA at a level of less than, or equal to, 140 TPM (transcripts per million). Compounds of formula (I) may be used against cancers resistant to gemcitabine, cytarabine, temozolomide, of 5-fluorouracil. Compounds of formula (I) may be used in conjunction with other anticancer agents (e.g. 5-FU). Also disclosed is a method of treating or preventing cancer.